Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30 -0.2% 149.20 149.10 149.20 150.50 147.50 147.50 287,043 15:00:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 473.2 -126.5 -14.6 - 1,095

Indivior Share Discussion Threads

Showing 3451 to 3470 of 3750 messages
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
DateSubjectAuthorDiscuss
25/7/2020
13:11
First Half and Second Quarter 2020 Financial Results on July 30th suggest waiting for reaction to results and future outlook
waldron
25/7/2020
12:30
Anyone have a sensible near term price target here?
hodhasharon
25/7/2020
11:39
Sue the DoJ ? Good luck they have the entire balance sheet of the US Government behind them
the stigologist
25/7/2020
11:35
the "minimum 3 billion" statement from the DoJ (which was not mentioned in the RNS last year) turned out to be scandalous. I have a good mind to sue
dealy
25/7/2020
10:35
Sharenow,shareday,tobby3 and many more .....all these posters arrived on 18 July are clearly emanating from the same source and target 'active' bulletin boards.There is quite clearly an unhealthy ulterior motive.
steeplejack
25/7/2020
10:14
Steeplejack, reference the penultimate para of your extract where it talks of EBIDA risking running negative over the next 12 to 18 months! Many a slip of course, but it rather amused me when until very recently many folks were projecting there just wasn't going to be a next period -full stop!
gregmorg
25/7/2020
10:04
CHEERS JACK Https://www.thisismoney.co.uk/money/markets/article-8557569/MARKET-REPORT-Indivior-shares-soar-scandal-ends.html
the grumpy old men
25/7/2020
09:51
Today 00:36Indivior Still Faces Uncertain Future Despite US Case End - Moody'sFri, 24th Jul 2020 21:38Alliance News(Alliance News) - Indivior PLC still faces uncertainties, but Moody's Investors Service on Friday said the conclusion of a criminal case in the US was a step in the right direction.The ratings agency affirmed the pharmaceutical firm's B3 corporate family rating and upgraded its probability of default rating to B3-PD from Caa1-PD.The outlook on these ratings was lifted to stable from negative.Indivior on Friday said it will part with USD600 million to resolve criminal charges in the US related to its Suboxone film to treat opioid dependence medication.The company in April 2019 said a grand jury in the Western District of Virginia has issued an indictment of 28 felony counts against the company related to fraud.The felonies, issued in connection with a federal criminal investigation initiated by the US Department of Justice in 2013, include one count of conspiracy to commit mail, wire and health care fraud; one count of health care fraud; four counts of mail fraud; and 22 counts of wire fraud.Indivior could have faced USD3 billion in fines related to the matters."Moody's views the settlement a credit negative, as settlement payments will consume cash over several years. Partially offsetting these cash outflows related to the settlement is Indivior's significant cash balance of more than USD900 million," Moody's said."Supporting the outlook revision to stable is Moody's view that Indivior's DOJ settlement payments will be manageable with Indivior's significant cash balances. Moody's expects that Indivior's cash is sufficient to support strategic investments for the ongoing commercialisation of Sublocade and Perseris over the next 18 months, and a working capital unwind associated with sales rebates and returns within Medicaid."Indivior still faces "key uncertainties to the future of its business", the ratings agency said."Successful uptake of its newer products, Sublocade and Perseris, is critical for more than offsetting erosion of its Suboxone Film product to generic competition. Commercial success in both of these products will require significant investment which risk EBITDA running negative over the next 12 to 18 months," Moody's added.Indivior shares closed 38% higher at 119.60 pence each in London on Friday.
steeplejack
24/7/2020
20:17
INDV chart is nice but not sure how it becomes a £5 stock again without a new blockbuster (INDV2000 /C4X3256 ?)
the stigologist
24/7/2020
19:42
Incredible chart this Finally after 2 years C4XD have broken above the 200 day Moving Average and broken a long medium term downtrend There's a gap from c.20p to 40p that needs filling This could and should go vertical in coming weeks It has totally missed UK biotech boom because the market was so worried that their one licensee Indivior would be 1) made bankrupt and/or 2) not be allowed to sell through US Government programmes Both those threats taken off the table INDV could easily make the decision that it makes sense for them to buy C4XD for £40m or £60m or £80m and thus save themselves $294m in licence milestones and royalties Meanwhile C4XD like EVG have a NRF2 compound which is highly promising along with an IL17 one. Both could be licenced by bigger biotechs/pharmas to be taken into clinic
the stigologist
24/7/2020
16:27
Yes that's certainly true,Sublocade now moves back centre stage.
steeplejack
24/7/2020
16:20
Certainly if it hangs around at this price then it seems to me that someone will take it off us! Possibly the Company need some better Sublocade sales to complete the circle.
gregmorg
24/7/2020
16:08
300p target
hodhasharon
24/7/2020
16:06
Having more nuclear weapons that anyone else is good as a starter.
steeplejack
24/7/2020
16:05
INDV could now buy out C4XD C4XD Market Cap £15m but they have a $294m deal with INDV Why would INDV pay out $294m when they could easily just pay a 200% premium for C4XD and take it out now for say £45m !
the stigologist
24/7/2020
16:03
Interesting that the fine is going to paid slowly but surely over a number of years.Now it's just a question of whether the company can make any money.Of course,now the case has been settled,an element of bid premium can be factored back in or is that wishful thinking :)
steeplejack
24/7/2020
16:02
Price (GBX) 130.00 49.86% Open / Last close - / 86.75 High / Low 135.40 / 83.35 Bid / Offer 128.50 / 131.70
waldron
24/7/2020
15:59
Well - that should put it into the weekend press 😀. Good news at last and removal of the major uncertainty that has been hanging over this share.glah. DL
davidlloyd
24/7/2020
15:58
How come Americans can bully and impose massive fines on British companies but it doesn't work the other way round?? Aren't the Americans supposed to be our friends and the Chinese our enemies???
pngasef
24/7/2020
15:57
$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 110 to 120p
waldron
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210512 14:17:47